Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice

References

• Naka N, Tomita Y, Nakanishi H, Araki N, Hongyo T, Ochi T, Aozasa K. Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer 1997; 71:952 - 5; http://dx.doi.org/10.1002/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.0.CO;2-X; PMID: 9185695
   PubMed Web of Science ®Google Scholar
• Rathmell WK, Acs G, Simon MC, Vaughn DJ. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 2004; 24:167 - 9; PMID: 15015593
   PubMed Web of Science ®Google Scholar
• Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241 - 7; http://dx.doi.org/10.1097/00130404-200505000-00011; PMID: 16053668
   PubMed Web of Science ®Google Scholar
• Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010; 11:983 - 91; http://dx.doi.org/10.1016/S1470-2045(10)70023-1; PMID: 20537949
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Naka N, Tomita Y, Kawamori D, Kanno H, Aozasa K. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995; 75:2867 - 74; http://dx.doi.org/10.1002/1097-0142(19950615)75:12<2867::AID-CNCR2820751212>3.0.CO;2-8; PMID: 7773935
   PubMed Web of Science ®Google Scholar
• Zindy F, Nilsson LM, Nguyen L, Meunier C, Smeyne RJ, Rehg JE, Eberhart C, Sherr CJ, Roussel MF. Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Res 2003; 63:5420 - 7; PMID: 14500377
   PubMed Web of Science ®Google Scholar
• Krump-Konvalinkova V, Bittinger F, Olert J, Bräuninger W, Brunner J, Kirkpatrick CJ. Establishment and characterization of an angiosarcoma-derived cell line, AS-M. Endothelium 2003; 10:319 - 28; http://dx.doi.org/10.1080/714007546; PMID: 14741847
   PubMed Web of Science ®Google Scholar
• Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691 - 703; http://dx.doi.org/10.1016/j.cell.2007.06.054; PMID: 17719546
   PubMed Web of Science ®Google Scholar
• Tokuyama W, Mikami T, Masuzawa M, Okayasu I. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol 2010; 41:407 - 14; http://dx.doi.org/10.1016/j.humpath.2009.08.021; PMID: 19913279
   PubMed Web of Science ®Google Scholar
• Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010; 22:351 - 5; http://dx.doi.org/10.1097/CCO.0b013e32833aaad4; PMID: 20485168
   PubMed Web of Science ®Google Scholar
• Taylor SM, Nevis KR, Park HL, Rogers GC, Rogers SL, Cook JG, Bautch VL. Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 2010; 116:3108 - 17; http://dx.doi.org/10.1182/blood-2010-01-266197; PMID: 20664058
   PubMed Web of Science ®Google Scholar
• Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009; 175:2657 - 67; http://dx.doi.org/10.2353/ajpath.2009.090202; PMID: 19875502
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64:8249 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-04-1567; PMID: 15548691
   PubMed Web of Science ®Google Scholar
• De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011; 21:73 - 9; http://dx.doi.org/10.1016/j.gde.2010.10.008; PMID: 21106363
   PubMed Web of Science ®Google Scholar
• Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, Löhrs U. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998; 153:1425 - 33; http://dx.doi.org/10.1016/S0002-9440(10)65729-X; PMID: 9811333
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr., Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14:16 - 22; http://dx.doi.org/10.1002/mc.2940140105; PMID: 7546219
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356:215 - 21; http://dx.doi.org/10.1038/356215a0; PMID: 1552940
   PubMed Web of Science ®Google Scholar
• Harvey M, McArthur MJ, Montgomery CA Jr., Bradley A, Donehower LA. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 1993; 7:938 - 43; PMID: 8344491
   PubMed Web of Science ®Google Scholar
• Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001; 61:6952 - 7; PMID: 11559575
   PubMed Web of Science ®Google Scholar
• Qin G, Kishore R, Dolan CM, Silver M, Wecker A, Luedemann CN, Thorne T, Hanley A, Curry C, Heyd L, et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A 2006; 103:11015 - 20; http://dx.doi.org/10.1073/pnas.0509533103; PMID: 16835303
   PubMed Web of Science ®Google Scholar
• Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, Hulpiau P, Haigh K, Haenebalcke L, Drogat B, et al. p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death Differ 2013; 20:888 - 97; http://dx.doi.org/10.1038/cdd.2013.12; PMID: 23449391
   PubMed Web of Science ®Google Scholar
• Kisanuki YYHR, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 2001; 230:230 - 42; http://dx.doi.org/10.1006/dbio.2000.0106; PMID: 11161575
   PubMed Web of Science ®Google Scholar
• Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29:418 - 25; http://dx.doi.org/10.1038/ng747; PMID: 11694875
   PubMed Web of Science ®Google Scholar
• Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126:1149 - 59; PMID: 10021335
   PubMed Web of Science ®Google Scholar
• Morse HC 3rd, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan SC, MacLennan IC, Pattengale PK, et al, Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002; 100:246 - 58; http://dx.doi.org/10.1182/blood.V100.1.246; PMID: 12070034
   PubMed Web of Science ®Google Scholar
• Rehg JE, Ward JM. Morphological and immunohistochemical characterization of sarcomatous tumors in wild-type and genetically engineered mice. Vet Pathol 2012; 49:206 - 17; http://dx.doi.org/10.1177/0300985811429813; PMID: 22146848
   PubMed Web of Science ®Google Scholar
• Harvey M, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993; 5:225 - 9; http://dx.doi.org/10.1038/ng1193-225; PMID: 8275085
   PubMed Web of Science ®Google Scholar
• Goossens S, Janzen V, Bartunkova S, Yokomizo T, Drogat B, Crisan M, Haigh K, Seuntjens E, Umans L, Riedt T, et al. The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization. Blood 2011; 117:5620 - 30; http://dx.doi.org/10.1182/blood-2010-08-300236; PMID: 21355089
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96:2240 - 5; PMID: 10979972
   PubMed Web of Science ®Google Scholar
• Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn 2006; 235:3413 - 22; http://dx.doi.org/10.1002/dvdy.20982; PMID: 17072878
   PubMed Web of Science ®Google Scholar
• Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M. Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis 2008; 46:74 - 80; http://dx.doi.org/10.1002/dvg.20367; PMID: 18257043
   PubMed Web of Science ®Google Scholar
• Zovein AC, Hofmann JJ, Lynch M, French WJ, Turlo KA, Yang Y, Becker MS, Zanetta L, Dejana E, Gasson JC, et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell 2008; 3:625 - 36; http://dx.doi.org/10.1016/j.stem.2008.09.018; PMID: 19041779
   PubMed Web of Science ®Google Scholar
• Martín-Caballero J, Flores JM, García-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61:6234 - 8; PMID: 11507077
   PubMed Web of Science ®Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582 - 4; http://dx.doi.org/10.1126/science.7521539; PMID: 7521539
   PubMed Web of Science ®Google Scholar
• Masuzawa M, Fujimura T, Tsubokawa M, Nishiyama S, Katsuoka K, Terada E, Kunita S, Sakurai Y, Kato H. Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1). J Dermatol Sci 1998; 16:91 - 8; http://dx.doi.org/10.1016/S0923-1811(97)00032-7; PMID: 9459120
   PubMed Web of Science ®Google Scholar
• Masuzawa M, Fujimura T, Hamada Y, Fujita Y, Hara H, Nishiyama S, Katsuoka K, Tamauchi H, Sakurai Y. Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J Cancer 1999; 81:305 - 8; http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2<305::AID-IJC22>3.0.CO;2-Z; PMID: 10188735
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008; 8:579 - 91; http://dx.doi.org/10.1038/nrc2403; PMID: 18596824
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232 - 9; http://dx.doi.org/10.1016/j.ccr.2009.01.021; PMID: 19249681
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220 - 31; http://dx.doi.org/10.1016/j.ccr.2009.01.027; PMID: 19249680
   PubMed Web of Science ®Google Scholar
• Zape JP, Zovein AC. Hemogenic endothelium: origins, regulation, and implications for vascular biology. Semin Cell Dev Biol 2011; 22:1036 - 47; http://dx.doi.org/10.1016/j.semcdb.2011.10.003; PMID: 22001113
   PubMed Web of Science ®Google Scholar
• Hayashibara T, Fujimoto T, Miyanishi T, Yamada Y, Maita T, Kamihira S, Tomonaga M. Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients. Leukemia 1999; 13:1634 - 5; http://dx.doi.org/10.1038/sj.leu.2401546; PMID: 10516769
   PubMed Web of Science ®Google Scholar